Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 3/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936981 | 1.00 | CYP1A2 (0.39) | CYP1A2CYP2A6HKDC1AHRNR4A2 | |
| SCHEMBL29344203 | 0.77 | HKDC1 (0.49) | CYP1A2CYP2A6HKDC1AHRNR4A2 | |
| SCHEMBL29937238 | 0.77 | HKDC1 (0.49) | CYP1A2CYP2A6HKDC1AHRNR4A2 | |
| SCHEMBL31178562 | 0.77 | HKDC1 (0.45) | CYP1A2CYP2A6HKDC1AHRNR4A2 | |
| SCHEMBL23043385 | 0.73 | HKDC1 (0.58) | CYP1A2CYP2A6HKDC1AHRNR4A2 | |
| SCHEMBL31504059 | 0.73 | ALDH1A1 (0.50) | CYP1A2CYP2A6HKDC1AHR | |
| SCHEMBL29418744 | 0.73 | HKDC1 (0.58) | CYP1A2CYP2A6HKDC1AHRNR4A2 | |
| SCHEMBL29344205 | 0.72 | CYP1A2 (0.38) | CYP1A2CYP2A6HKDC1AHRNR4A2 | |
| SCHEMBL20788048 | 0.69 | CYP1A2 (0.44) | CYP1A2CYP2A6AHRNR4A2 | |
| SCHEMBL25242361 | 0.69 | CYP1A2 (0.35) | CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | CYP1A2 4576/4885CYP2A6 3523/4885HKDC1 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.